Skip to content

Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital

Diabeloop WP6-1 : Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02101229
Acronym
WP6-1
Enrollment
17
Registered
2014-04-02
Start date
2014-05-31
Completion date
2015-02-28
Last updated
2015-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

Glycemic control algorithm, closed loop, artificial pancreas

Brief summary

To assess whether the DIABELOOP algorithm provides better glycemic control than the usual algorithm of T1D patients on pump therapy: * at meals, with CHO roughly assessed by the patient. * during and after physical activity sessions qualified as moderate by the patient. Primary endpoint : time within the glycemic reference range. The study will be conduct with 15 patients at the following investigation centers : Corbeil Hospital, CHU of Grenoble, and CHU of Montpellier.

Detailed description

The 15 patients will have 2 visits during 24 hours (day and night), once with their usual algorithm and once with the Diabeloop system.

Interventions

the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient

Sponsors

Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient type 1 diabetic for at least one year * Patient treated by external insulin pump for at least 6 months * Patients with HbA1c \<9% * Patient affiliated with Social Security. * Patient able to perform two tests of physical activity of 30 minutes (one event in each treatment period); * aged at least 18 years Patient; * Patient who signed consent

Exclusion criteria

* All serious disease that could interfere with the study * BMI \> 30 kg/m2 * insulin requirement \> 2 U/kg/day * Patient benefiting from a measure of legal protection; * Pregnant or likely to be women.

Design outcomes

Primary

MeasureTime frameDescription
Time spent in blood glucose range [70-180 mg/dl]up to 24 hours after each treatment periodcomparing the time spent in \[70-180 mg/dl\] with usual algorithm vs Diabeloop algorithm.

Secondary

MeasureTime frameDescription
Time spent Blood Glucose range [80-140 mg/dl]24 hours after each treatment periodComparing the time spent in range \[80-140 mg/dl\] with usual algorithm vs Diabeloop algorithm
time spent below 70 mg/dl and above 180 mg/dlup to 24 hours after each treatment period

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026